From a 17th-century pharmacy to the Vioxx scandal and the cure for river blindness, we explore the complex legacy of pharmaceutical giant Merck & Co.

[INTRO]

ALEX: In 1987, the CEO of Merck sat in his office and made a decision that would cost his company billions of dollars in potential revenue, yet he did it anyway. He decided to give away a drug called Mectizan for free, forever, to anyone in the world who needed it to prevent blindness.

JORDAN: Wait, a pharmaceutical giant just gave away the goods? There has to be a catch. Companies that big don't usually prioritize charity over their shareholders.

ALEX: That’s the central tension of Merck & Co. It’s a company built on the credo that 'medicine is for the people, not for the profits,' yet it also authored one of the deadliest drug safety scandals in history. Today, we’re looking at the double-edged sword of modern medicine through the lens of a company that started in a literal angel pharmacy.

[CHAPTER 1 - Origin]

ALEX: The story actually begins in 1668 in Darmstadt, Germany. A man named Friedrich Jacob Merck bought something called the 'Angel Pharmacy.' For over two centuries, his family built it into a major chemical powerhouse.

JORDAN: So how does a German family pharmacy become a massive American corporation? That’s a long way from home.

ALEX: It wasn’t exactly a planned move. In 1891, George Merck moved to New York to set up a U.S. branch for the family business. They were mostly importing chemicals from Germany and manufacturing morphine and codeine in New Jersey.

JORDAN: Let me guess—World War I happened and things got complicated?

ALEX: Exactly. When the U.S. entered the war in 1917, the government viewed Merck as a German enemy entity. They literally confiscated the company under the 'Trading with the Enemy Act' and took 80% of its stock.

JORDAN: So the U.S. government owned Merck? How did the family get it back?

ALEX: George’s son, George W. Merck, had to buy his own company back at a public auction in 1919 using public financing. This creates a weird quirk of history: there are actually two totally separate Mercks today. There’s the American Merck & Co., and the original German Merck KGaA. They aren’t allowed to use the 'Merck' name in each other’s territories.

[CHAPTER 2 - Core Story]

ALEX: Once independent, George W. Merck pivoted the company from just mixing chemicals to hardcore scientific research. He built massive labs in the 1930s during the Great Depression, which was a huge gamble.

JORDAN: Did the gamble pay off, or were they just burning cash while everyone else was standing in bread lines?

ALEX: It paid off in ways that changed the world. They synthesized Vitamin C first. They funded the discovery of streptomycin, the first big antibiotic for tuberculosis. In 1950, George W. Merck gave a famous speech saying the profits follow the people, not the other way around.

JORDAN: That sounds great for a PR brochure, but did they actually live it? Or was it just mid-century corporate-speak?

ALEX: For a while, they really did. In the 1980s, under CEO Roy Vagelos, they developed a drug for River Blindness. They realized the people who needed it most—poor villagers in Africa—could never afford it. So, they just gave it away. They’ve delivered billions of treatments since then and essentially wiped out the disease in several countries.

JORDAN: Okay, I’ll give them credit for that. But you mentioned a scandal. When does the 'medicine is for the people' part fall apart?

ALEX: It falls apart with a drug called Vioxx. Launched in 1999, it was a blockbuster painkiller meant to be easier on the stomach than aspirin. It was making over 2 billion dollars a year.

JORDAN: Usually, when a drug is that successful that fast, there’s a 'but.' What was the 'but' for Vioxx?

ALEX: The 'but' was that Vioxx was doubling the risk of heart attacks and strokes. Internal studies showed warning signs as early as 2000, but the company kept marketing it aggressively directly to consumers.

JORDAN: So they ignored the science to protect the cash flow? That’s the exact opposite of their founding mission.

ALEX: It was a disaster. In 2004, Merck finally pulled Vioxx from the shelves after their own trial confirmed the danger. They faced nearly 30,000 lawsuits and eventually paid roughly 4.8 billion dollars to settle them. It nearly destroyed their reputation for scientific integrity.

JORDAN: How do you even come back from that? If I'm a doctor or a patient, why would I trust anything from them again?

ALEX: They had to go back to the lab. They shifted focus to oncology and developed a drug called Keytruda. It’s an immunotherapy that helps your own immune system fight cancer cells. Today, it’s one of the best-selling drugs in the world, bringing in 25 billion dollars a year and treating dozens of different types of cancer.

[CHAPTER 3 - Why It Matters]

JORDAN: So Merck is basically the poster child for the 'Blockbuster Drug' model. They find one miracle pill, ride it for billions until the patent runs out, and then scramble for the next one?

ALEX: Exactly. It’s a high-stakes cycle. They are currently spending over 30 billion dollars a year on research and acquisitions because their patent on Keytruda expires in 2028. They have to find the next miracle before then or they’ll face a 'patent cliff' where revenue just vanishes.

JORDAN: It seems like they’re constantly balancing between being a humanitarian organization and a ruthless hedge fund for molecules.

ALEX: That is the legacy. They created the first measles vaccine and the first statin for cholesterol, which saved millions of lives. But they also show us the danger when a company’s need for the next billion-dollar hit outweighs its commitment to safety.

JORDAN: What’s the one thing to remember about Merck?

ALEX: Merck proves that while scientific innovation can change the world, the integrity of the data matters just as much as the breakthrough itself.

JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai